Evidence that lithium protects against tardive dyskinesia: The Curaçao Extrapyramidal Syndromes study VI

European Neuropsychopharmacology

Volumn 18, Issue 2, 2008, Pages 152-155

  van Harten, Peter N ^a,b,e   Hoek, Hans W ^b,c,d   Matroos, Glenn E ^e,f   van Os, Jim ^g,h  

^a Symfora Group Psychiatric Center   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e Dr DR Capriles Hospital   (Netherlands Antilles)

^f Psychiatric Associaton Antilles ^*  (Netherlands Antilles)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Course; Follow up study; Incidence; Lithium; Neuroprotective; Tardive dyskinesia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LITHIUM; NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT RATING SCALE; ADULT; AFRICAN CARIBBEAN; ARTICLE; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NETHERLANDS ANTILLES; NEUROPROTECTION; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; AGED; ANTIMANIC AGENTS; CARIBBEAN REGION; COHORT STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 37349057889     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.07.004     Document Type: Article

References (23)

1. APA. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association (1992), The American Psychiatric Association, Washington
2. Cohen J. A power primer. Psychol. Bull. 112 1 (1992) 155-159
3. Correll C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161 (2004) 414-425
4. Coulter D.M., Bate A., and Meyboom R.H.B. Antipsychotic drugs and heart muscle disorder in international pharmacovigiliance: data mining study. BMJ 321 (2001) 1371-1376
5. Egan M.F., Hyde T.M., Albers G.W., Elkashef A., Alexander R.C., Reeve A., Blum A., Saenz R.E., and Wyatt R.J. Treatment of tardive dyskinesia with vitamin E. Am. J. Psychiatry 149 (1992) 773-777
6. Gould T.D., and Manji H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30 (2005) 1223-1237
7. Kane J.M., Woerner M., Borenstein M., Wegner J., and Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol. Bull. 22 (1986) 254-258
8. Koro C.E., Fedder D.O., and I'Talien GJ. Assessment of the independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-controlled study. BMJ (2002) 325-343
9. Leucht S., Kissling W., and McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J. Clin. Psychiatry 65 (2004) 177-186
10. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
11. Manji H.K., Moore G.J., and Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?. Biol. Psychiatry 46 (1999) 929-940
12. Manji H.K., Moore G.J., and Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol. Psychiatry 48 (2000) 740-754
13. Margolese H.C., Chouinard G., Kolivakis T.T., Beauclair L., and Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J. Psychiatry 50 (2005) 541-547
14. Moore G.J., Bebchuk J.M., Hasanat K., et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biol. Psychiatry 48 (2000) 1-8
15. Moore G.J., Bebchuk J.M., Wilds I.B., Chen G., Manji H.K., and Menji HK. Lithium-induced increase in human brain grey matter. Lancet 356 (2000) 1241-1242
16. Morgenstern H., and Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiatry 50 (1993) 723-733
17. Procyshyn R.M., Kennedy N.B., and Tse G. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can. J. Psychiatry 46 (2001) 334-339
18. Shamir E., Barak Y., Shalman I., Laudon M., Zisapel N., Tarrasch R., Elizur A., and Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch. Gen. Psychiatry 58 (2001) 1049-1052
19. Smith J.M., Kucharski L.T., Eblen C., Knutsen E., and Linn C. An assessment of tardive dyskinesia in schizophrenic outpatients. Psychopharmacology (Berl) 64 (1979) 99-104
20. Stata base reference manual (2003): release 8.
21. van Harten P.N., Matroos G.E., Hoek H.W., and Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia. The Curacao Extrapyramidal Syndromes Study: I. Schizophr. Res. 19 (1996) 195-203
22. Van Harten P.N., Hoek H.W., Matroos G.E., and van Os J. Incidence of tardive dyskinesia and tardive dystonia in African-Caribbean patients on long term antipsychotic treatment. The Curaçao Extrapyramidal Syndromes Study: V. J. Clin. Psychiatry 67 (2006) 1920-1927
23. Woerner M.G., Alvir J.M., Saltz B.L., Lieberman J.A., and Kane J.M. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am. J. Psychiatry 155 (1998) 1521-1528